SEC I	Form 4	

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

							V	Vashing	gton, D.C	. 2054	49					(ОМВ	APPRO\	/AL	
Section 16. Form 4 or Form 5 obligations may continue. See							TOF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
transac contrac the pur securit to satis	chase or sale or ies of the issue ify the affirmativ ons of Rule 10t	pursuant to a written plan for of equity r that is intended ve defense																		
1. Name and Address of Reporting Person [*] FONTEYNE PAUL R.					Apellis Pharmaceuticals, Inc. [APLS] (Check all ap								eck all applic	tor 10% Owner						
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/01/2025									Officer below)	(give title		Other (specify below)			
100 FIFT (Street) WALTH		E, 3RD FLOOR	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Join Line) V Form filed									pint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting			1					
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	n-Deriva	ative	e Se	curities	s Acq	uired,	Disp	osed o	of, or	Ben	eficiall	y Owned					
Date				2. Transa Date (Month/E			2A. Deemed Execution Date, if any (Month/Day/Year		Code (Insti					5. Amour Securitie Beneficia Owned F Reported	s Form ally (D) o ollowing (I) (In		: Direct c r Indirect E str. 4) 0	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				,	
Common	Stock			01/01	/2025			A ⁽¹⁾		6,26	6,267 A		\$ <mark>0</mark>	22,705			D			
		-	Table II -												Owned					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Ye		3A. Deemee Execution I if any (Month/Day	d 4. Date, Ti	ransaction ode (Instr.		5. Number of		, options, conve 6. Date Exercisable an Expiration Date (Month/Day/Year)		able and	7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		Amount s ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	ode	v	(A) (D)		Date Exercisab		xpiration ate			Amount or Number of Shares						
Stock Option (Right to Buy)	\$31.91	01/01/2025			A		11,199		(2)	1	2/31/2032	Com Sto		11,199	\$ 0	11,199	9	D		
•	n of Respons	ses: was granted on Janua	m 1 2025 T	ha ractrict	d ct-	ale '	6		the first		and the second	dat-	farrent	aubia-t.t.	his continu	L comitat a		tor or	atar	
		a director at his elec	tion.	ne restricte	u stoc	ck uni	t will fully	vest on	the first at	miver	sary or the	uare o	i grant,	subject to	ins continued	i service as	a urec	tor, or upon la	ater	

This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.

/s/ David Watson, attorney-in-01/03/2025 fact for Paul Fonteyne

F

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.